-
Together,for a brighter futureTo emerge as the global trailblazer in pharmaceutical-grade amino acid technology, propelling innovation and advancement across the healthcare industry
-
Delivering transformative solutions for human healthDeveloping personalized amino acid-based solutions dedicated to enhancing human nutrition and wellness
News & Updates
Plumino has acquired the pharmaceutical, food and feed-grade, amino acids, and Human Milk Oligosaccharides (HMOs) businesses and related assets from Kyowa Hakko Bio Co., Ltd.
Kyowa Hakko Bio, established on October 1, 2008, traces its origins to the Biochemical Division of Kyowa Hakko Kogyo Co., Ltd. founded in 1949. As a pioneer in amino acid fermentation technology, Kyowa Hakko Bio specialized in producing high-purity, pharmaceutical-grade amino acids through advanced fermentation processes for extensive applications in pharmaceuticals and healthcare.
Leveraging Kyowa Hakko Bio’s 70+ years of technological expertise, Plumino will continue to explore biotechnology frontiers. We are poised to drive innovation and excellence in biotechnology and amino acid research, continually expanding the possibilities within the life science industry.
Where Tech Meets Human Needs
Guided by the integration of innovation and pragmatism, Plumino continuously explores new frontiers in biotechnology to deliver enhanced value for customers, partners, and the broader society.
Rising Above
Seeing Beyond
Deep technological heritage
Though a new market entrant, Plumino has secured a strong foundation by building upon Kyowa Hakko Bio's seven-decade legacy. Our team combines extensive industry expertise with specialized capabilities, integrating Kyowa's medical-grade amino acids and HMO assets through pragmatic business execution and continuous innovation to deliver reliable solutions for customers.
When seven decades of scientific excellence converges with emerging synthetic biology, we create limitless possibilities.
Amino Acids × Synthetic Biology: Unlocking Endless Possibilities
Leveraging cutting-edge synthetic biology as our innovation engine, we continuously drive the deep integration of biotechnology and industrial manufacturing. By building green, intelligent, and efficient innovation ecosystems, we harness technological power to reshape future industries and pioneer the new wave of sustainable intelligent manufacturing.
Through dual-drive technological breakthroughs and product development, we transform groundbreaking biotechnologies into market-leading innovations, injecting new momentum into industry advancement.
Stay on top of what we're up to
-
Plumino Officially Launches: Pioneering Innovation and Sustainability in the Global Amino Acid IndustryOn April 30, 2025, Plumino, a new enterprise dedicated to becoming a global leader in the amino acid sector, officially announced its establishment. Plumino will deliver core value to customers worldwide through its exceptional high-quality amino acid products and comprehensive professional solutions across all categories.
2025.04.30 -
Plumino Group Completes its Acquisition of Kyowa Hakko Bio's amino acid and HMO businesses[July 1, 2025] Plumino Precision Fermentation Holdings Pte. Ltd. (hereinafter the “Plumino Group”), an emerging synthetic biology platform with deep industrial expertise in microbial fermentation and a strategic focus on pharmaceutical ingredients and nutritional health solutions, today announced the successful completion of its acquisition of the amino acids and Human Milk Oligosaccharides (“HMOs”) businesses of Kyowa Hakko Bio Co., Ltd. (hereinafter “Kyowa Hakko Bio”).
2025.07.01
